Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.

Targeting the hERG1/β1 integrin complex in lipid rafts potentiates statins anti-cancer activity in pancreatic cancer

Open access

Abstract

Plasma membrane macromolecular complexes function as signaling hubs that regulate cell behavior, which is particularly relevant in cancer. Our study provides evidence that the complex formed by the hERG1 potassium channel and the β1 subunit of integrin receptors preferentially localizes in Lipid Rafts (LRs) in Pancreatic Ductal Adenocarcinoma (PDAC) cell lines and primary samples. The complex recruits the p85 subunit of phosphatidyl-inositol-3-kinase (PI3K), activating phosphoinositide metabolism and triggering an intracellular signaling pathway centered on Akt. This pathway ultimately affects cancer cell proliferation through cyclins and p21, and cell migration through the small GTPase Rac-1 and f-actin organization. The hERG1/β1 integrin complex in LRs can be dissociated and the downstream signaling pathway can be inhibited by either disrupting LRs through methyl-beta-cyclodextrin (MβCD) or inhibiting cholesterol synthesis by statins. Treatment with a single chain bispecific antibody—scDb-hERG1-β1—specifically targeting the complex significantly potentiates the effects of both MβCD and statins on intracellular signaling. Consequently, these treatments decrease PDAC cell proliferation and motility in vitro. From a pharmacological perspective, different statins produce anti-neoplastic effects in synergy with scDb-hERG1-β1. Such combination also enhances tumor sensitivity to chemotherapeutic drugs, such as gemcitabine and oxaliplatin. The efficacy of these combination treatments depends on the amount of the hERG1/β1 integrin complex present on the plasma membrane of cancer cells. Finally, the combined treatment with statins and scDb-hERG1-β1 significantly reduces tumor growth and improves survival in vivo, in a preclinical mouse model. These results suggest that the combination of scDb-hERG1-β1 and statins represent a potential novel strategy for treating PDAC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41420-025-02321-2

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Localization of hERG1 and of the hERG1/β1 integrin complex in lipid rafts in PDAC cells after cell adhesion on Fibronectin. A Representative membrane of lipid rafts localization of hERG1/β1 integrin complex in PANC-1 cells. As a control, we also analyzed the distribution of two marker proteins, one of which (caveolin-1) is highly enriched in the raft fractions (4–6) and one (transferrin receptor/CD71) is mainly distributed in the Triton-soluble fractions (9–11). The panels on the right show the densitometric analysis of the fractions of the sucrose gradient. Bars indicate the percentage distribution across the gel of raft fractions 4–6 (Triton X-100 insoluble fractions) and non- rafts fractions 9–11 (Triton X-100 soluble fractions), as detected by scanning densitometric analysis; quantitation of each enriched protein was normalized over the corresponding marker, i.e caveolin-1 for raft fractions and transferrin receptor/CD71 for non-raft fractions. The density of each band in the same gel was analyzed, values were totaled, and then the percent distribution across the gel was detected and reported in the bar graphs on the right as densitometric units (%) for Triton X-100-insoluble fractions (4–6) and Triton X-100-soluble fractions (9–11). B Representative membrane of Triton X-100-insoluble fractions (4–6) and Triton X-100-soluble fractions (9–11) of PANC-1 cells immunoprecipitated with anti-hERG1 mAb and incubated with Cholera Toxin B Subunit Peroxidase to detect GM1 (left panel) and corresponding densiometric quantification of GM1 normalized over hERG1 immunoprecipitates(right panel). Data are representative of three independent experiments (n = 3). a.u.= arbitrary units. C Representative membrane of Triton X-100-insoluble fractions (4–6) and Triton X-100-soluble fractions (9–11) of PANC-1 cells, immunoprecipitated with mAb hERG1 and incubated with anti-Integrin β1 pAb (RM12 Ab) (left panel) and corresponding densiometric quantification of β1 Integrin over hERG1 immunoprecipitates (right panel). Data are representative of three independent experiments (n = 3). a.u.= arbitrary units. D Representative membrane of Triton X-100-insoluble fractions (4–6) and Triton X-100-soluble fractions (9–11) of HEK293-hERG1 cells, immunoprecipitated with mAb hERG1 and incubated with anti-Integrin β1 pAb (RM12 Ab) (left panel) and densiometric quantification β1 Integrin over hERG1 immunoprecipitates (right panel). Data are representative of three independent experiments (n = 3). a.u. = arbitrary units. E Representative membrane of co-IPs between β1 integrin, hERG1, caveolin-1 and flotillin-1 in HEK-hERG1 cells after cell seeding on FN for 90 min (left panel). Total cell proteins were immunoprecipitated with anti-β1 integrin mAb (TS2/16). An IgG isotypic control was employed too. Cells were seeded on BSA or FN coated dishes for 90 min. HEK 293 were used as control. Right panel: densitometric analysis. Protein lysates used for IP quantification, indicated as “inputs”, are reported in figure; protein lysates not used for IP quantification, indicated as “inputs”, are reported in Supplementary Fig. 1 (panel A). Data are representative of three independent experiments (n = 3). a.u. = arbitrary units. F Co-IP between hERG1 and β1 integrin, Co-IP between hERG1, β1 integrin, caveolin-1 and Co-IP between hERG1, β1 integrin, flotillin in normal and PDAC cells, following 90 min adhesion onto BSA or FN. Protein lysates used for IP quantification, indicated as “inputs”, are reported in figure; protein lysates not used for IP quantification, indicated as “inputs”, are reported in Supplementary Fig. 1 (panel B). Total cell proteins were immunoprecipitated with anti-β1 integrin mAb (TS2/16). An IgG isotypic control was employed. Top panel: representative WB of the co-IP; Bottom panel: densitometric analysis. Total lysates indicated as “inputs” are reported in figure. Data are representative of three independent experiments (n = 3). a.u. = arbitrary units. All data are presented as mean values ± s.e.m. Co-IP between hERG1 and β1 integrin: BSA vs FN: **P < 0.01: PANC-1, MiaPaca2, BxPC3; ***P < 0.001: HPDE FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: HPDE FN vs BxPC3 FN; ***P < 0.001: RLT-PSC FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: RLT-PSC FN FN vs BxPC3 FN. Co-IP between hERG1, β1 integrin, caveolin-1: BSA vs FN: **P < 0.01: PANC-1, MiaPaca2, BxPC3; ***P < 0.001: HPDE FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: HPDE FN vs BxPC3 FN; ***P < 0.001: RLT-PSC FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: RLT-PSC FN FN vs BxPC3 FN. Co-IP between hERG1, β1 integrin, flotillin: **P < 0.01: PANC-1, MiaPaca2, BxPC3; ***P < 0.001: HPDE FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: HPDE FN vs BxPC3 FN; ***P < 0.001: RLT-PSC FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: RLT-PSC FN FN vs BxPC3 FN. **P < 0.01, and ***P < 0.001. All data are presented as mean values ± s.e.m. *P < 0.05 and ***P < 0.001 (one-way ANOVA). Insol insoluble fraction, Sol soluble fraction, Input total lysate, BSA bovine serum albumin, FN Fibronectin, St standard.
Fig. 1 Localization of hERG1 and of the hERG1/β1 integrin complex in lipid rafts in PDAC cells after cell adhesion on Fibronectin. A Representative membrane of lipid rafts localization of hERG1/β1 integrin complex in PANC-1 cells. As a control, we also analyzed the distribution of two marker proteins, one of which (caveolin-1) is highly enriched in the raft fractions (4–6) and one (transferrin receptor/CD71) is mainly distributed in the Triton-soluble fractions (9–11). The panels on the right show the densitometric analysis of the fractions of the sucrose gradient. Bars indicate the percentage distribution across the gel of raft fractions 4–6 (Triton X-100 insoluble fractions) and non- rafts fractions 9–11 (Triton X-100 soluble fractions), as detected by scanning densitometric analysis; quantitation of each enriched protein was normalized over the corresponding marker, i.e caveolin-1 for raft fractions and transferrin receptor/CD71 for non-raft fractions. The density of each band in the same gel was analyzed, values were totaled, and then the percent distribution across the gel was detected and reported in the bar graphs on the right as densitometric units (%) for Triton X-100-insoluble fractions (4–6) and Triton X-100-soluble fractions (9–11). B Representative membrane of Triton X-100-insoluble fractions (4–6) and Triton X-100-soluble fractions (9–11) of PANC-1 cells immunoprecipitated with anti-hERG1 mAb and incubated with Cholera Toxin B Subunit Peroxidase to detect GM1 (left panel) and corresponding densiometric quantification of GM1 normalized over hERG1 immunoprecipitates(right panel). Data are representative of three independent experiments (n = 3). a.u.= arbitrary units. C Representative membrane of Triton X-100-insoluble fractions (4–6) and Triton X-100-soluble fractions (9–11) of PANC-1 cells, immunoprecipitated with mAb hERG1 and incubated with anti-Integrin β1 pAb (RM12 Ab) (left panel) and corresponding densiometric quantification of β1 Integrin over hERG1 immunoprecipitates (right panel). Data are representative of three independent experiments (n = 3). a.u.= arbitrary units. D Representative membrane of Triton X-100-insoluble fractions (4–6) and Triton X-100-soluble fractions (9–11) of HEK293-hERG1 cells, immunoprecipitated with mAb hERG1 and incubated with anti-Integrin β1 pAb (RM12 Ab) (left panel) and densiometric quantification β1 Integrin over hERG1 immunoprecipitates (right panel). Data are representative of three independent experiments (n = 3). a.u. = arbitrary units. E Representative membrane of co-IPs between β1 integrin, hERG1, caveolin-1 and flotillin-1 in HEK-hERG1 cells after cell seeding on FN for 90 min (left panel). Total cell proteins were immunoprecipitated with anti-β1 integrin mAb (TS2/16). An IgG isotypic control was employed too. Cells were seeded on BSA or FN coated dishes for 90 min. HEK 293 were used as control. Right panel: densitometric analysis. Protein lysates used for IP quantification, indicated as “inputs”, are reported in figure; protein lysates not used for IP quantification, indicated as “inputs”, are reported in Supplementary Fig. 1 (panel A). Data are representative of three independent experiments (n = 3). a.u. = arbitrary units. F Co-IP between hERG1 and β1 integrin, Co-IP between hERG1, β1 integrin, caveolin-1 and Co-IP between hERG1, β1 integrin, flotillin in normal and PDAC cells, following 90 min adhesion onto BSA or FN. Protein lysates used for IP quantification, indicated as “inputs”, are reported in figure; protein lysates not used for IP quantification, indicated as “inputs”, are reported in Supplementary Fig. 1 (panel B). Total cell proteins were immunoprecipitated with anti-β1 integrin mAb (TS2/16). An IgG isotypic control was employed. Top panel: representative WB of the co-IP; Bottom panel: densitometric analysis. Total lysates indicated as “inputs” are reported in figure. Data are representative of three independent experiments (n = 3). a.u. = arbitrary units. All data are presented as mean values ± s.e.m. Co-IP between hERG1 and β1 integrin: BSA vs FN: **P < 0.01: PANC-1, MiaPaca2, BxPC3; ***P < 0.001: HPDE FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: HPDE FN vs BxPC3 FN; ***P < 0.001: RLT-PSC FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: RLT-PSC FN FN vs BxPC3 FN. Co-IP between hERG1, β1 integrin, caveolin-1: BSA vs FN: **P < 0.01: PANC-1, MiaPaca2, BxPC3; ***P < 0.001: HPDE FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: HPDE FN vs BxPC3 FN; ***P < 0.001: RLT-PSC FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: RLT-PSC FN FN vs BxPC3 FN. Co-IP between hERG1, β1 integrin, flotillin: **P < 0.01: PANC-1, MiaPaca2, BxPC3; ***P < 0.001: HPDE FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: HPDE FN vs BxPC3 FN; ***P < 0.001: RLT-PSC FN vs PANC-1 FN, MiaPaca2 FN; **P < 0.01: RLT-PSC FN FN vs BxPC3 FN. **P < 0.01, and ***P < 0.001. All data are presented as mean values ± s.e.m. *P < 0.05 and ***P < 0.001 (one-way ANOVA). Insol insoluble fraction, Sol soluble fraction, Input total lysate, BSA bovine serum albumin, FN Fibronectin, St standard.CC BY · PubMed Central
Fig. 2 Localization of the hERG1/β1 integrin complex in lipid rafts in human primary PDAC samples. A Representative IHC images of scDb-hERG1-β1 and caveolin-1 staining in normal sample (top panel) and PDAC samples (bottom panels). The normal sample is positive for caveolin-1 and negative for scDb-hERG1-β1. The PDAC sample in the middle panel is positive for scDb-hERG1-β1 and caveolin-1. The PDAC sample in the bottom panel is negative for scDb-hERG1-β1 and caveolin-1. Scale bar: 100 μm. B Expression of hERG1-β1 complex, caveolin-1 in normal pancreas and PDAC samples. The number of negative and positive (and the corresponding percentage) samples for the two biomarkers are reported. The p values of Fisher’s Exact test and Pearson Correlation Coefficient are reported. C Heat map and Pearson correlation coefficient between scDb-hERG1-β1 and caveolin-1 in normal samples (left panel) and in PDAC samples (right panel). D Representative IF images showing co-localization of hERG1-β1 integrin complex and caveolin-1 in a PDAC tissue sample. Sample was stained with scDb-hERG1-β1 alexa-488 conjugated and anti-caveolin-1 antibody revealed with Alexa-546-anti-mouse secondary antibody. From left to right, scDb-hERG1-β1-alexa488, caveolin-1, Hoechst staining and Merge images are reported (scale bar: 100 µm).
Fig. 2 Localization of the hERG1/β1 integrin complex in lipid rafts in human primary PDAC samples. A Representative IHC images of scDb-hERG1-β1 and caveolin-1 staining in normal sample (top panel) and PDAC samples (bottom panels). The normal sample is positive for caveolin-1 and negative for scDb-hERG1-β1. The PDAC sample in the middle panel is positive for scDb-hERG1-β1 and caveolin-1. The PDAC sample in the bottom panel is negative for scDb-hERG1-β1 and caveolin-1. Scale bar: 100 μm. B Expression of hERG1-β1 complex, caveolin-1 in normal pancreas and PDAC samples. The number of negative and positive (and the corresponding percentage) samples for the two biomarkers are reported. The p values of Fisher’s Exact test and Pearson Correlation Coefficient are reported. C Heat map and Pearson correlation coefficient between scDb-hERG1-β1 and caveolin-1 in normal samples (left panel) and in PDAC samples (right panel). D Representative IF images showing co-localization of hERG1-β1 integrin complex and caveolin-1 in a PDAC tissue sample. Sample was stained with scDb-hERG1-β1 alexa-488 conjugated and anti-caveolin-1 antibody revealed with Alexa-546-anti-mouse secondary antibody. From left to right, scDb-hERG1-β1-alexa488, caveolin-1, Hoechst staining and Merge images are reported (scale bar: 100 µm).CC BY · PubMed Central
Fig. 3 Effects of MβCD and scDb-hERG1-β1 treatment on hERG1/β1 integrin complex in PDAC cells after cell adhesion on Fibronectin. A Flow cytometry plots of hERG1 expression onto the plasma membrane in HEK-HERG1 and PANC-1 cells following 90 min adhesion onto FN with or without treatment with 5 mM MβCD for 20 min [48]. Values are expressed as mean fluorescence intensity of the area under the curve (MFI). Representative plots are on the left, while quantitative analyses are reported in the graphs on the right. a.u. = arbitrary units Data are mean values ± s.e.m. obtained from three independent experiments (n = 3). B Co-IP between hERG1 and β1 integrin on HEK-hERG1 and PANC-1 cells following 90 min adhesion onto FN with and without treatment with 5 mM MβCD and corresponding densitometric analysis. Total cell proteins were immunoprecipitated with anti-β1 integrin mAb (TS2/16). An IgG isotypic control was employed too. Left panel: representative WB of the co-IP; Right panel: densitometric analysis. The WBs relative to the inputs are in figure and in Supplementary Fig. 3. Data are representative of three independent experiments (n = 3). a.u.= arbitrary units. C IF performed on HEK-hERG1 and PANC-1 cells following 90 min adhesion onto FN with or without treatment with 5 mM MβCD. Representative images (scale bar: 100 μm) of scDb-hERG1-β1 staining is on the right. a.u.= arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. D HEK-hERG1 and PANC-1 cells following 90 min adhesion onto FN with or without treatment with 5 mM MβCD. Representative images (scale bar: 100 μm) of caveolin-1 staining and colocalization between scDb-hERG1-β1 and caveolin-1 are on the left, while quantitative analyses (fluorescent intensity and Mander’s Overlapping Coefficient, MOC) are reported in the graphs on the right. a.u.= arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. E IF performed on PANC-1 cells following 90 min adhesion onto FN with or without treatment with scDb-hERG1-β1 (20 μg/ml). Representative images of colocalization between scDb-hERG1-β1 and caveolin-1 (scale bar: 100 μm) are on the left, while quantitative analyses (MOC) are reported in the graph on the right. a.u. = arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. F Co-IP between hERG1 and PI3K p85 in PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20ug/ml), and their combination, seeded on FN for 90 min. Total cell proteins were immunoprecipitated with anti-hERG1 mAb. Left panel: representative WB of the co-IP; Right panel: densitometric analysis. Total lysates indicated as “inputs” are reported in Supplementary Fig. 3. Data are representative of three independent experiments (n = 3). a.u. = arbitrary units. G IF performed on PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20 µg/ml), and their combination, seeded on FN for 90 min. Representative images of PIP2 (top panels) and PIP3 (bottom panels) (scale bar: 50 μm) are on the top, while quantitative analyses (Mean fluorescence intensity) are reported in the graph on the bottom. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. Lower magnification images are reported in Supplementary Fig. 3. H Representative blot (left) and densitometric analysis (right) of ERK and phospho-ERK levels in PANC-1 cells untreated (CTR) or treated with scDb-hERG1-β1 (20 µg/ml), MβCD (5 mM) and their combination, seeded on FN for 90 min and a negative control, labeled BSA. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with anti-pAkt Thr308, anti-Akt Thr308, ERK1/2 (pERK1/2) (Thr202/tyr204) and anti-total ERK1/2 antibodies. CTR control, MβCD Methyl-β-cyclodextrin, MOC Mander’s Overlapping Coefficient, IP immunoprecipitation, BSA bovine serum albumin. All data are presented as mean values ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA).
Fig. 3 Effects of MβCD and scDb-hERG1-β1 treatment on hERG1/β1 integrin complex in PDAC cells after cell adhesion on Fibronectin. A Flow cytometry plots of hERG1 expression onto the plasma membrane in HEK-HERG1 and PANC-1 cells following 90 min adhesion onto FN with or without treatment with 5 mM MβCD for 20 min [48]. Values are expressed as mean fluorescence intensity of the area under the curve (MFI). Representative plots are on the left, while quantitative analyses are reported in the graphs on the right. a.u. = arbitrary units Data are mean values ± s.e.m. obtained from three independent experiments (n = 3). B Co-IP between hERG1 and β1 integrin on HEK-hERG1 and PANC-1 cells following 90 min adhesion onto FN with and without treatment with 5 mM MβCD and corresponding densitometric analysis. Total cell proteins were immunoprecipitated with anti-β1 integrin mAb (TS2/16). An IgG isotypic control was employed too. Left panel: representative WB of the co-IP; Right panel: densitometric analysis. The WBs relative to the inputs are in figure and in Supplementary Fig. 3. Data are representative of three independent experiments (n = 3). a.u.= arbitrary units. C IF performed on HEK-hERG1 and PANC-1 cells following 90 min adhesion onto FN with or without treatment with 5 mM MβCD. Representative images (scale bar: 100 μm) of scDb-hERG1-β1 staining is on the right. a.u.= arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. D HEK-hERG1 and PANC-1 cells following 90 min adhesion onto FN with or without treatment with 5 mM MβCD. Representative images (scale bar: 100 μm) of caveolin-1 staining and colocalization between scDb-hERG1-β1 and caveolin-1 are on the left, while quantitative analyses (fluorescent intensity and Mander’s Overlapping Coefficient, MOC) are reported in the graphs on the right. a.u.= arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. E IF performed on PANC-1 cells following 90 min adhesion onto FN with or without treatment with scDb-hERG1-β1 (20 μg/ml). Representative images of colocalization between scDb-hERG1-β1 and caveolin-1 (scale bar: 100 μm) are on the left, while quantitative analyses (MOC) are reported in the graph on the right. a.u. = arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. F Co-IP between hERG1 and PI3K p85 in PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20ug/ml), and their combination, seeded on FN for 90 min. Total cell proteins were immunoprecipitated with anti-hERG1 mAb. Left panel: representative WB of the co-IP; Right panel: densitometric analysis. Total lysates indicated as “inputs” are reported in Supplementary Fig. 3. Data are representative of three independent experiments (n = 3). a.u. = arbitrary units. G IF performed on PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20 µg/ml), and their combination, seeded on FN for 90 min. Representative images of PIP2 (top panels) and PIP3 (bottom panels) (scale bar: 50 μm) are on the top, while quantitative analyses (Mean fluorescence intensity) are reported in the graph on the bottom. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. Lower magnification images are reported in Supplementary Fig. 3. H Representative blot (left) and densitometric analysis (right) of ERK and phospho-ERK levels in PANC-1 cells untreated (CTR) or treated with scDb-hERG1-β1 (20 µg/ml), MβCD (5 mM) and their combination, seeded on FN for 90 min and a negative control, labeled BSA. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with anti-pAkt Thr308, anti-Akt Thr308, ERK1/2 (pERK1/2) (Thr202/tyr204) and anti-total ERK1/2 antibodies. CTR control, MβCD Methyl-β-cyclodextrin, MOC Mander’s Overlapping Coefficient, IP immunoprecipitation, BSA bovine serum albumin. All data are presented as mean values ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA).CC BY · PubMed Central
Fig. 4 Effects of MβCD and scDb-hERG1-β1 treatment on intracellular signaling triggered by cell adhesion on Fibronectin in PDAC cells. A Representative blot (top) and densitometric analysis (bottom) of Rac-1 activation assay in PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20 µg/ml) and their combination, seeded on FN for 90 min. GDP was used as negative control and GTPγS was used as positive control. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with Rac-1 antibody. Inputs of total Rac-1 and tubulin are reported in the figure. B IF images of PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20 µg/ml) and their combination, seeded on FN for 90 min, stained with anti-ARP2/3 antibody and Cortical F actin (left panels). Scale bar: 100 µm. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. Quantification graphs of ARP2/3 fluorescent intensity and cortical F-actin density were reported in the right panels. (ARP2/3 Fluorescence intensity) MβCD vs scDb-hERG1-β1: p = 0.02. scDb-hERG1-β1 vs MβCD+scDb-hERG1-β1: p = 0.01. (Cortical F-actin density) MβCD vs scDb-hERG1-β1: p = 0.04. scDb-hERG1-β1 vs MβCD+scDb-hERG1-β1: p = 0.02. C Lateral motility experiments onto FN were performed on PANC-1 cells treated with MβCD (5 mM), scDb-hERG1-β1 (20 μg/ml) and their combination onto FN for 90 min. Representative images are reported in the left panel. The motility is reported as graph of percentage of cell motility in the right panel. Scale bar: 100 µm. Data are presented as mean values ± s.e.m. (n = 3). (D) Representative blot (top) and densitometric analysis (bottom) of Cyclin D, Cyclin E and p21 in PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20 µg/ml) and their combination, seeded on FN for 90 min and a negative control, labeled BSA. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with anti-Cyclin D, anti-Cyclin E and anti-p21 antibodies. E Flow cytometry (FC) plots of cell cycle of PANC-1 cells treated with MβCD (5 mM), scDb-hERG1-β1 (20 μg/ml) and their combination for 24 h. MβCD vs CRT: p = 0.005 (G1); p = 0.042 (S); p = 0.041 (G2/M). scDb-hERG1-β1 vs CRT: p = 0.005 (G1); p = 0.038 (S); p = 0.039 (G2/M). MβCD+scDb-hERG1-β1 vs CTR: p = 0.0003 (G1); p = 0.001 (S); p = 0.0002 (G2/M). Data are presented as mean values ± s.e.m. (n = 3). F Integrin controlled macromolecular hubs centered on hERG1 and lipid rafts and their possible involvement in pancreatic ductal adenocarcinoma. Created with BioRender.com. *P < 0.05; **P < 0.01, and ***P < 0.001 (one-way ANOVA). GDP guanosine diphosphate, GTPγS G-protein-activating analog of guanosine triphosphate, CTR control, MβCD Methyl-β-cyclodextrin, MOC Mander’s Overlapping Coefficient, IP immunoprecipitation, BSA bovine serum albumin.
Fig. 4 Effects of MβCD and scDb-hERG1-β1 treatment on intracellular signaling triggered by cell adhesion on Fibronectin in PDAC cells. A Representative blot (top) and densitometric analysis (bottom) of Rac-1 activation assay in PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20 µg/ml) and their combination, seeded on FN for 90 min. GDP was used as negative control and GTPγS was used as positive control. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with Rac-1 antibody. Inputs of total Rac-1 and tubulin are reported in the figure. B IF images of PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20 µg/ml) and their combination, seeded on FN for 90 min, stained with anti-ARP2/3 antibody and Cortical F actin (left panels). Scale bar: 100 µm. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. Quantification graphs of ARP2/3 fluorescent intensity and cortical F-actin density were reported in the right panels. (ARP2/3 Fluorescence intensity) MβCD vs scDb-hERG1-β1: p = 0.02. scDb-hERG1-β1 vs MβCD+scDb-hERG1-β1: p = 0.01. (Cortical F-actin density) MβCD vs scDb-hERG1-β1: p = 0.04. scDb-hERG1-β1 vs MβCD+scDb-hERG1-β1: p = 0.02. C Lateral motility experiments onto FN were performed on PANC-1 cells treated with MβCD (5 mM), scDb-hERG1-β1 (20 μg/ml) and their combination onto FN for 90 min. Representative images are reported in the left panel. The motility is reported as graph of percentage of cell motility in the right panel. Scale bar: 100 µm. Data are presented as mean values ± s.e.m. (n = 3). (D) Representative blot (top) and densitometric analysis (bottom) of Cyclin D, Cyclin E and p21 in PANC-1 cells untreated (CTR) or treated with MβCD (5 mM), scDb-hERG1-β1 (20 µg/ml) and their combination, seeded on FN for 90 min and a negative control, labeled BSA. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with anti-Cyclin D, anti-Cyclin E and anti-p21 antibodies. E Flow cytometry (FC) plots of cell cycle of PANC-1 cells treated with MβCD (5 mM), scDb-hERG1-β1 (20 μg/ml) and their combination for 24 h. MβCD vs CRT: p = 0.005 (G1); p = 0.042 (S); p = 0.041 (G2/M). scDb-hERG1-β1 vs CRT: p = 0.005 (G1); p = 0.038 (S); p = 0.039 (G2/M). MβCD+scDb-hERG1-β1 vs CTR: p = 0.0003 (G1); p = 0.001 (S); p = 0.0002 (G2/M). Data are presented as mean values ± s.e.m. (n = 3). F Integrin controlled macromolecular hubs centered on hERG1 and lipid rafts and their possible involvement in pancreatic ductal adenocarcinoma. Created with BioRender.com. *P < 0.05; **P < 0.01, and ***P < 0.001 (one-way ANOVA). GDP guanosine diphosphate, GTPγS G-protein-activating analog of guanosine triphosphate, CTR control, MβCD Methyl-β-cyclodextrin, MOC Mander’s Overlapping Coefficient, IP immunoprecipitation, BSA bovine serum albumin.CC BY · PubMed Central
Fig. 5 Effects of SIMVASTATIN (SIM) and of scDb-hERG1-β1 treatment on intracellular signaling triggered by cell adhesion on Fibronectin in PDAC cells. A PANC-1 and HEK-hERG1 cells untreated or treated with SIM or MβCD were subject to cholesterol quantification by HPTLC. Quantitative analysis of separated free cholesterol was carried out using NIH Image1.62 as software. B IF performed on PANC-1 cells following 90 min adhesion onto FN with or without treatment with SIM, scDb-hERG1-β1 and their combination. Representative images (scale bar: 100 μm) of caveolin-1 staining, scDb-hERG1-β1 staining and colocalization between caveolin-1 and scDb-hERG1-β1 are on the top, while quantitative analyses and MOC are reported in the graphs on the bottom. a.u.= arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. C IF performed on PANC-1 cells untreated (CTR) or treated with SIM (4.7 μM), scDb-hERG1-β1 (20 µg/ml), and their combination, seeded on FN for 90 min. Representative images of PIP2 (top panels) and PIP3 (bottom panels) (scale bar: 50 μm) are on the top, while quantitative analyses (Mean fluorescence intensity) are reported in the graph on the bottom. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. D Representative blot (top) and densitometric analysis (bottom) of phospho-Akt and phospho-ERK levels in PANC-1 cells untreated (CTR) or treated with SIM (4.7 µM), scDb-hERG1-β1 (20 µg/ml) and their combination, seeded on FN for 90 min. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with anti-pAkt Thr308, anti-Akt Thr308, ERK1/2 (pERK1/2) (Thr202/tyr204) and anti-total ERK1/2 antibodies. E IF on PANC-1 cells stained with anti-ARP2/3 antibody and cortical F-actin (left panels) after treatment with SIM (4.7 μM), scDb-hERG1-β1 (20 µg/ml) and their combination onto FN for 90 min (scale bar: 100 μm). At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. Quantification graphs of ARP2/3 fluorescent intensity and cortical F-actin density were reported in the right panels. Data are presented as mean values ± s.e.m. F Representative blot (top) and densitometric analysis (bottom) of Cyclin D, Cyclin E and p21 in PANC-1 cells untreated (CTR) or treated with scDb-hERG1-β1 (20ug/ml), SIM (4.7 µM) and their combination, seeded on FN for 90 min. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with anti-Cyclin D, anti-Cyclin E and anti-p21 antibodies. *P < 0.05; **P < 0.01, and ***P < 0.001 (one-way ANOVA). CTR control, MβCD Methyl-β-cyclodextrin, SIM simvastatin, CHOL Free cholesterol, TGs triglycerides, CEs cholesterol esters, MOC Mander’s Overlapping Coefficient.
Fig. 5 Effects of SIMVASTATIN (SIM) and of scDb-hERG1-β1 treatment on intracellular signaling triggered by cell adhesion on Fibronectin in PDAC cells. A PANC-1 and HEK-hERG1 cells untreated or treated with SIM or MβCD were subject to cholesterol quantification by HPTLC. Quantitative analysis of separated free cholesterol was carried out using NIH Image1.62 as software. B IF performed on PANC-1 cells following 90 min adhesion onto FN with or without treatment with SIM, scDb-hERG1-β1 and their combination. Representative images (scale bar: 100 μm) of caveolin-1 staining, scDb-hERG1-β1 staining and colocalization between caveolin-1 and scDb-hERG1-β1 are on the top, while quantitative analyses and MOC are reported in the graphs on the bottom. a.u.= arbitrary units. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. C IF performed on PANC-1 cells untreated (CTR) or treated with SIM (4.7 μM), scDb-hERG1-β1 (20 µg/ml), and their combination, seeded on FN for 90 min. Representative images of PIP2 (top panels) and PIP3 (bottom panels) (scale bar: 50 μm) are on the top, while quantitative analyses (Mean fluorescence intensity) are reported in the graph on the bottom. At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. All data are presented as mean values ± s.e.m. D Representative blot (top) and densitometric analysis (bottom) of phospho-Akt and phospho-ERK levels in PANC-1 cells untreated (CTR) or treated with SIM (4.7 µM), scDb-hERG1-β1 (20 µg/ml) and their combination, seeded on FN for 90 min. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with anti-pAkt Thr308, anti-Akt Thr308, ERK1/2 (pERK1/2) (Thr202/tyr204) and anti-total ERK1/2 antibodies. E IF on PANC-1 cells stained with anti-ARP2/3 antibody and cortical F-actin (left panels) after treatment with SIM (4.7 μM), scDb-hERG1-β1 (20 µg/ml) and their combination onto FN for 90 min (scale bar: 100 μm). At least 20 cells (in 3 different fields) per condition from three independent experiments (n = 3) were analyzed. Quantification graphs of ARP2/3 fluorescent intensity and cortical F-actin density were reported in the right panels. Data are presented as mean values ± s.e.m. F Representative blot (top) and densitometric analysis (bottom) of Cyclin D, Cyclin E and p21 in PANC-1 cells untreated (CTR) or treated with scDb-hERG1-β1 (20ug/ml), SIM (4.7 µM) and their combination, seeded on FN for 90 min. Data are presented as mean values ± s.e.m. (n = 3). a.u. = arbitrary units. Membranes were probed with anti-Cyclin D, anti-Cyclin E and anti-p21 antibodies. *P < 0.05; **P < 0.01, and ***P < 0.001 (one-way ANOVA). CTR control, MβCD Methyl-β-cyclodextrin, SIM simvastatin, CHOL Free cholesterol, TGs triglycerides, CEs cholesterol esters, MOC Mander’s Overlapping Coefficient.CC BY · PubMed Central
Fig. 6 Effects of statins and scDb-hERG1-β1 treatments on PDAC cell vitality, proliferation and migration. A Proliferation curve of PANC-1 CTR and treated with IC50 of SIM for 24 h, 48 h, 72 h and 96 h. Data are presented as mean values ± s.e.m. (n = 3). B Representative Calcein/PI images of PANC-1 CTR and treated with IC50 of SIM, scDb-hERG1-β1 and IC50 of SIM + scDb-hERG1-β1 for 24 h, 48 h, 72 h and 96 h (left panel) (scale bar: 100 μm) and cell live index (%) graph (right panel). Data are presented as mean values ± s.e.m. (n = 3). C Facs plots of cell cycle of PANC-1 cells treated with with IC50 of SIM, scDb-hERG1-β1 and IC50 of SIM + scDb-hERG1-β1 for 24 h. SIM vs CRT: p = 0.004 (G1); p = 0.021 (S); p = 0.038 (G2/M). SIM vs scDb-hERG1-β1: p = 0.005 (G1); p = 0.038 (S); p = 0.039 (G2/M). SIM+ scDb-hERG1-β1 vs CRT: p = 0.0002 (G1); p = 0.001 (S); p = 0.0001 (G2/M). Data are presented as mean values ± s.e.m. (n = 3). D Graph of percentage live cells, PANC-1 (left panel) and MiaPaCa2 (right panel) cells, treated for 24 h with IC50 of SIM, FLUVA, LOVA, ATOR, scDb-hERG1-β1 and combination of each statin with scDb-hERG1-β1 are reported. Data are presented as mean values ± s.e.m. (n = 3). E Lateral motility experiments onto FN were performed on PANC-1 cells treated with SIM, FLUVA, LOVA, ATOR, scDb-hERG1-β1 (at IC50 values for 90 min) and combinations of each statin and scDb-hERG1-β1 (at IC50 values for 90 min). Representative images are reported in the left panel. The motility is reported as graph of percentage of cell motility in the right panel. Scale bar: 100 µm. Data are presented as mean values ± s.e.m. (n = 3). F Lateral motility experiments onto FN were performed on MiaPaCa2 cells treated with SIM, FLUVA, LOVA, ATOR, scDb-hERG1-β1 (at IC50 values for 90 min) and combinations of each statin and scDb-hERG1-β1 (at IC50 values for 90 min). Representative images are reported in the left panel. The motility is reported as graph of percentage of cell motility in the right panel. Scale bar: 100 µm. Data are presented as mean values ± s.e.m. (n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA). CTR control, SIM Simvastatin, FLUVA Fluvastatin, LOVA Lovastatin, ATOR Atorvastatin.
Fig. 6 Effects of statins and scDb-hERG1-β1 treatments on PDAC cell vitality, proliferation and migration. A Proliferation curve of PANC-1 CTR and treated with IC50 of SIM for 24 h, 48 h, 72 h and 96 h. Data are presented as mean values ± s.e.m. (n = 3). B Representative Calcein/PI images of PANC-1 CTR and treated with IC50 of SIM, scDb-hERG1-β1 and IC50 of SIM + scDb-hERG1-β1 for 24 h, 48 h, 72 h and 96 h (left panel) (scale bar: 100 μm) and cell live index (%) graph (right panel). Data are presented as mean values ± s.e.m. (n = 3). C Facs plots of cell cycle of PANC-1 cells treated with with IC50 of SIM, scDb-hERG1-β1 and IC50 of SIM + scDb-hERG1-β1 for 24 h. SIM vs CRT: p = 0.004 (G1); p = 0.021 (S); p = 0.038 (G2/M). SIM vs scDb-hERG1-β1: p = 0.005 (G1); p = 0.038 (S); p = 0.039 (G2/M). SIM+ scDb-hERG1-β1 vs CRT: p = 0.0002 (G1); p = 0.001 (S); p = 0.0001 (G2/M). Data are presented as mean values ± s.e.m. (n = 3). D Graph of percentage live cells, PANC-1 (left panel) and MiaPaCa2 (right panel) cells, treated for 24 h with IC50 of SIM, FLUVA, LOVA, ATOR, scDb-hERG1-β1 and combination of each statin with scDb-hERG1-β1 are reported. Data are presented as mean values ± s.e.m. (n = 3). E Lateral motility experiments onto FN were performed on PANC-1 cells treated with SIM, FLUVA, LOVA, ATOR, scDb-hERG1-β1 (at IC50 values for 90 min) and combinations of each statin and scDb-hERG1-β1 (at IC50 values for 90 min). Representative images are reported in the left panel. The motility is reported as graph of percentage of cell motility in the right panel. Scale bar: 100 µm. Data are presented as mean values ± s.e.m. (n = 3). F Lateral motility experiments onto FN were performed on MiaPaCa2 cells treated with SIM, FLUVA, LOVA, ATOR, scDb-hERG1-β1 (at IC50 values for 90 min) and combinations of each statin and scDb-hERG1-β1 (at IC50 values for 90 min). Representative images are reported in the left panel. The motility is reported as graph of percentage of cell motility in the right panel. Scale bar: 100 µm. Data are presented as mean values ± s.e.m. (n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA). CTR control, SIM Simvastatin, FLUVA Fluvastatin, LOVA Lovastatin, ATOR Atorvastatin.CC BY · PubMed Central
Fig. 7 Effects of statins, gemcitabine and oxaliplatin on cell vitality and migration in PDAC cells and PDAC hERG1 silenced cells. A Graph of percentage live cells in hERG1 silenced PANC-1, MiaPaCa2 and HEK 293 cells treated for 24 h with IC50 of SIM, FLUVA, LOVA, ATOR, scDb-hERG1-β1 and combination of each statin with scDb-hERG1-β1 is reported. The values of no hERG1 silenced PANC-1 and MiaPaCa2 cells are reported in gray bars. Data are presented as mean values ± s.e.m. (n = 3). B Lateral motility experiments onto FN performed on hERG1 silenced PANC-1 and MiaPaCa2 cells treated with SIM, FLUVA, LOVA, ATOR (at IC50 values for 90 min). The motility is reported as graph of percentage of cell motility; the values of no hERG1 silenced PANC-1 and MiaPaCa2 cells are reported in gray bars. Scale bar: 100 µm. Data are presented as mean values ± s.e.m. (n = 3). C Combination Index curves of PANC-1 and MiaPaCa2 cells CTR and treated with statins, GEM (left panel) and OXA (right panel). We combined the IC25, IC50, IC75 and IC100 of the two chemotherapeutic drugs with the IC25, IC50, IC75 and IC100 of the four statins, deriving these concentrations from the IC50 values shown in Table 1. The Combination Index for all treatments was then calculated. Data are presented as mean values ± s.e.m. (n = 3). D Combination Index curves of PANC-1 and MiaPaCa2 hERG1 silenced cells CTR and treated with statins, GEM (left panel) and OXA (right panel). Data are presented as mean values ± s.e.m. (n = 3). E LDH assay on PANC-1 3D cells treated with SIM (IC50 value), OXA (IC50 and IC25) and scDb-hERG1-β1 (20 µg/ml) for 48 h. The effects of treatment were evaluated through the LDH assay, and the data as shown as percentage of cytotoxicity (see “Materials and methods” for details). Data are presented as mean values ± s.e.m. (n = 3). F LDH assay on hERG1 silenced PANC-1 3D cells (pink bars) and samples transfected with Lipofectamine but no siRNAs, indicated as “Scramble” (light blue bars) PANC-1 3D cells treated with (IC50 value), OXA (IC50 and IC25) and scDb-hERG1-β1 (20 µg/ml) for 48 h. Representative images of 3D cells are reported in Supplementary Fig. 7. Data are presented as mean values ± s.e.m. (n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA). CTR control, IC inhibitory concentration, SIM Simvastatin, FLUVA Fluvastatin, LOVA Lovastatin, ATOR Atorvastatin, GEM gemcitabine, OXA oxaliplatin.
Fig. 7 Effects of statins, gemcitabine and oxaliplatin on cell vitality and migration in PDAC cells and PDAC hERG1 silenced cells. A Graph of percentage live cells in hERG1 silenced PANC-1, MiaPaCa2 and HEK 293 cells treated for 24 h with IC50 of SIM, FLUVA, LOVA, ATOR, scDb-hERG1-β1 and combination of each statin with scDb-hERG1-β1 is reported. The values of no hERG1 silenced PANC-1 and MiaPaCa2 cells are reported in gray bars. Data are presented as mean values ± s.e.m. (n = 3). B Lateral motility experiments onto FN performed on hERG1 silenced PANC-1 and MiaPaCa2 cells treated with SIM, FLUVA, LOVA, ATOR (at IC50 values for 90 min). The motility is reported as graph of percentage of cell motility; the values of no hERG1 silenced PANC-1 and MiaPaCa2 cells are reported in gray bars. Scale bar: 100 µm. Data are presented as mean values ± s.e.m. (n = 3). C Combination Index curves of PANC-1 and MiaPaCa2 cells CTR and treated with statins, GEM (left panel) and OXA (right panel). We combined the IC25, IC50, IC75 and IC100 of the two chemotherapeutic drugs with the IC25, IC50, IC75 and IC100 of the four statins, deriving these concentrations from the IC50 values shown in Table 1. The Combination Index for all treatments was then calculated. Data are presented as mean values ± s.e.m. (n = 3). D Combination Index curves of PANC-1 and MiaPaCa2 hERG1 silenced cells CTR and treated with statins, GEM (left panel) and OXA (right panel). Data are presented as mean values ± s.e.m. (n = 3). E LDH assay on PANC-1 3D cells treated with SIM (IC50 value), OXA (IC50 and IC25) and scDb-hERG1-β1 (20 µg/ml) for 48 h. The effects of treatment were evaluated through the LDH assay, and the data as shown as percentage of cytotoxicity (see “Materials and methods” for details). Data are presented as mean values ± s.e.m. (n = 3). F LDH assay on hERG1 silenced PANC-1 3D cells (pink bars) and samples transfected with Lipofectamine but no siRNAs, indicated as “Scramble” (light blue bars) PANC-1 3D cells treated with (IC50 value), OXA (IC50 and IC25) and scDb-hERG1-β1 (20 µg/ml) for 48 h. Representative images of 3D cells are reported in Supplementary Fig. 7. Data are presented as mean values ± s.e.m. (n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA). CTR control, IC inhibitory concentration, SIM Simvastatin, FLUVA Fluvastatin, LOVA Lovastatin, ATOR Atorvastatin, GEM gemcitabine, OXA oxaliplatin.CC BY · PubMed Central
Fig. 8 Effects of SIM and scDb-hERG1-β1 treatment in vivo in a PDAC mouse model. A Time course of the volumes of tumor masses of PANC-1 cells (top panel) growing in mice treated with SIM 40 mg/kg, SIM 80 mg/kg and combination with scDb-hERG1-β1 16 mg/kg. P Values obtained with one-way ANOVA analysis at day 51 of experiment are reported below: CTR vs. SIM 40 p: 0.6859; CTR vs. SIM 40+ scDb-hERG1-β1 p: 0.5012; CTR vs. SIM 80 p: 0.0415; CTR vs. SIM 80+ scDb-hERG1-β1 p: 0.0144; SIM 40 vs. SIM 40+ scDb-hERG1-β1 p: 0.9996; SIM 40 vs. SIM 80 p: 0.6028; SIM 40 vs. SIM 80+ scDb-hERG1-β1 p: 0.2637; SIM 40+ scDb-hERG1-β1 vs. SIM 80 p: 0.7959; SIM 40+ scDb-hERG1-β1 vs. SIM 80+ scDb-hERG1-β1 p: 0.4126; SIM 80 vs. SIM 80+ scDb-hERG1-β1 p: 0.1423. Schedule of treatment (bottom panel). B Representative US images of tumor masses with rendering from PANC-1 cells at day 51 of mice untreated (CTR) and treated with SIM 40 mg/kg, SIM 80 mg/kg and combination with scDb-hERG1-β1 16 mg/kg. C Photoacoustic images (left panels) and related bar graph of HB total levels (right panel). D Representative IHC images of ki67 staining of tumor masses (left panels) and corresponding bar graph (right panel) of mice untreated (CTR) and treated with SIM 40 mg/kg, SIM 80 mg/kg and combination with scDb-hERG1-β1 16 mg/kg; 100 µm scale bar. The p values of Log Rank Test for Survival analysis was the following: CTR vs SIM 80: 0.7428; CTR vs SIM 40: 0.9271; CTR vs SIM 40 ± scDb-hERG1-β1: 0.1612. **P < 0.01 and ***P < 0.001. CTR control, SIM simvastatin, HbTOT total hemoglobin.
Fig. 8 Effects of SIM and scDb-hERG1-β1 treatment in vivo in a PDAC mouse model. A Time course of the volumes of tumor masses of PANC-1 cells (top panel) growing in mice treated with SIM 40 mg/kg, SIM 80 mg/kg and combination with scDb-hERG1-β1 16 mg/kg. P Values obtained with one-way ANOVA analysis at day 51 of experiment are reported below: CTR vs. SIM 40 p: 0.6859; CTR vs. SIM 40+ scDb-hERG1-β1 p: 0.5012; CTR vs. SIM 80 p: 0.0415; CTR vs. SIM 80+ scDb-hERG1-β1 p: 0.0144; SIM 40 vs. SIM 40+ scDb-hERG1-β1 p: 0.9996; SIM 40 vs. SIM 80 p: 0.6028; SIM 40 vs. SIM 80+ scDb-hERG1-β1 p: 0.2637; SIM 40+ scDb-hERG1-β1 vs. SIM 80 p: 0.7959; SIM 40+ scDb-hERG1-β1 vs. SIM 80+ scDb-hERG1-β1 p: 0.4126; SIM 80 vs. SIM 80+ scDb-hERG1-β1 p: 0.1423. Schedule of treatment (bottom panel). B Representative US images of tumor masses with rendering from PANC-1 cells at day 51 of mice untreated (CTR) and treated with SIM 40 mg/kg, SIM 80 mg/kg and combination with scDb-hERG1-β1 16 mg/kg. C Photoacoustic images (left panels) and related bar graph of HB total levels (right panel). D Representative IHC images of ki67 staining of tumor masses (left panels) and corresponding bar graph (right panel) of mice untreated (CTR) and treated with SIM 40 mg/kg, SIM 80 mg/kg and combination with scDb-hERG1-β1 16 mg/kg; 100 µm scale bar. The p values of Log Rank Test for Survival analysis was the following: CTR vs SIM 80: 0.7428; CTR vs SIM 40: 0.9271; CTR vs SIM 40 ± scDb-hERG1-β1: 0.1612. **P < 0.01 and ***P < 0.001. CTR control, SIM simvastatin, HbTOT total hemoglobin.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Cited by

See all 9

Metadata

Authors
Duranti, C., Iorio, J., Manganelli, V., Bagni, G., Colasurdo, R., Lottini, T., Martinelli, M., Capitani, C., Boso, G., D’Alessandro, F. N., Sorice, M., Becchetti, A., Misasi, R., Garofalo, T., & Arcangeli, A.
Affiliations
  • University of Florence (IT)
  • Sapienza University of Rome (IT)
  • University of Siena (IT)
  • University of Milano-Bicocca (IT)
Corresponding author
Arcangeli, Annarosa
Venue
Cell Death Discovery
Published
2025-02-03
Volume
11
Issue
1
Pages
39-39
ISSN
2058-7716 (ISSN-L)
OpenAlex
W4407104486
Cited by
8
References
81
Citations by year
2026: 6 · 2025: 2
FWCI
3.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death Discovery (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Florence Research (University of Florence) (submittedVersion, cc-by)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
  • Università degli Studi di Firenze (ex 60%)
  • Associazione Italiana per la Ricerca sul Cancro (1662, 15627, 21510)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
hERG1, beta1 integrin, lipid rafts, pancreatic ductal adenocarcinoma, statins, PI3K/Akt signaling, phosphoinositide metabolism, bispecific antibodies, methyl-β-cyclodextrin, cholesterol biosynthesis, cell proliferation, cell migration, Rac1, gemcitabine, oxaliplatin, combination therapy, tumor growth

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the hERG1/β1 integrin complex in lipid rafts potentiates statins anti-cancer activity in pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41420-025-02321-2
The paper
Duranti, C., Iorio, J., Manganelli, V., Bagni, G., Colasurdo, R., Lottini, T., Martinelli, M., Capitani, C., Boso, G., D’Alessandro, F. N., Sorice, M., Becchetti, A., Misasi, R., Garofalo, T., & Arcangeli, A. (2025). Targeting the hERG1/β1 integrin complex in lipid rafts potentiates statins anti-cancer activity in pancreatic cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-025-02321-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.